Leica Biosystems to Acquire Devicor Medical Products, Inc.
Buffalo Grove, Ill. – (Dec. 2nd, 2014) – Leica Biosystems, a global leader in anatomic pathology laboratory solutions and instruments, announced today that it has successfully completed its previously announced acquisition of Devicor Medical Products, Inc.
Devicor is a global market leader in breast biopsy instruments and consumables, with annual revenues of approximately $170 million. It is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Among Devicor’s products is the Original Mammotome Breast Biopsy System, which, to date, has enabled more than four million women to have a minimally invasive breast biopsy.
“Leica’s Biosystems’ products and solutions address the key steps across the anatomic pathology laboratory workflow. The addition of Devicor’s market leading breast biopsy products, especially Mammotome, allows us to further integrate that workflow from the source, starting with the patient and the biopsy sample,” said Matthias Weber, MD, President of Leica Biosystems. “This acquisition supports our mission of advancing cancer diagnostics to improve lives by adding products that will have direct benefits for the patients and the clinicians who care for them.”
Devicor will operate as a standalone business within Leica Biosystems and will continue to be led by Tom Daulton, the current CEO of Devicor. No other financial terms and conditions have been disclosed.
About Leica Biosystems
Leica Biosystems, is a global leader in anatomic pathology workflow solutions and automation, striving to advance cancer diagnostics to improve patients’ lives. Leica Biosystems provides anatomic pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica Biosystems’ easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 8 countries, sales and service organizations in 27 countries, and a network of dealers spanning the globe. The company is headquartered in Nussloch, Germany. Visit www.LeicaBiosystems.com for more information.
LEICA and the Leica logo are registered trademarks of Leica Microsystems